We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-5.01%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$7.85B
AUM Growth
-$933M
Cap. Flow
-$365M
Cap. Flow %
-4.65%
Top 10 Hldgs %
37.02%
Holding
151
New
11
Increased
33
Reduced
26
Closed
20

Top Buys

Rank Stock Value
1
ELV icon
Elevance Health
ELV
+$137M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$91.8M
3
AET
Aetna Inc
AET
+$82.5M
4
HUM icon
Humana
HUM
+$78.7M
5
MRK icon
Merck
MRK
+$68M

Top Sells

Rank Stock Value
1
WCG
Wellcare Health Plans, Inc.
WCG
+$146M
2
MOH icon
Molina Healthcare
MOH
+$117M
3
ESRX
Express Scripts Holding Company
ESRX
+$102M
4
IPXL
Impax Laboratories, Inc.
IPXL
+$89.8M
5
ABBV icon
AbbVie
ABBV
+$79.7M

Sector Composition

Rank Sector Weight
1 Healthcare 94.02%
2 Financials 1.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AFMD
101
DELISTED
Affimed
AFMD
$6.08M 0.08%
337,500
– –
CLLS
102
Cellectis
CLLS
$287M
$5.93M 0.08%
350,000
– –
SYRE icon
103
Spyre Therapeutics
SYRE
$8.35B
$5.92M 0.08%
54,409
– –
RDHL
104
Redhill Biopharma
RDHL
$4.26M
$5.91M 0.08%
565
– –
SNDX icon
105
Syndax Pharmaceuticals
SNDX
$1.68B
$5.43M 0.07%
757,365
– –
ZBH icon
106
Zimmer Biomet
ZBH
$18.7B
$5.06M 0.06%
50,470
-688,555
-93% -$73.8M
INFI
107
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$4.39M 0.06%
3,250,300
– –
ROKA
108
DELISTED
Sorrento Tech, Inc. Common Stock
ROKA
$3.79M 0.05%
893,470
+571,427
+177% +$2.88M
NVTA
109
DELISTED
Invitae Corporation
NVTA
$3.63M 0.05%
456,666
– –
AMED
110
DELISTED
Amedisys
AMED
$3.05M 0.04%
71,500
– –
ADAP
111
DELISTED
Adaptimmune Therapeutics
ADAP
$2.93M 0.04%
724,184
– –
BHC icon
112
Bausch Health
BHC
$1.7B
$2.83M 0.04%
194,900
– –
CLSD
113
DELISTED
Clearside Biomedical
CLSD
$2.68M 0.03%
+20,000
New +$5.02M
PTCT icon
114
PTC Therapeutics
PTCT
$6.15B
$2.23M 0.03%
+204,400
New +$2.14M
SGMO
115
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$2.16M 0.03%
707,400
-124,100
-15% -$452K
AMRN
116
Amarin Corp
AMRN
$300M
$1.08M 0.01%
17,500
– –
BLRX
117
BioLineRX
BLRX
$12.3M
$956K 0.01%
1,731
– –
NVLN
118
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$842K 0.01%
+100,000
New +$886K
MRNS
119
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$573K 0.01%
141,900
– –
XYLO
120
DELISTED
Xylo Technologies
XYLO
$339K ﹤0.01%
375
– –
ARLZ
121
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
$301K ﹤0.01%
68,143
– –
ALIM
122
DELISTED
Alimera Sciences
ALIM
$270K ﹤0.01%
16,667
– –
XTNT icon
123
Xtant Medical Holdings
XTNT
$59.1M
$261K ﹤0.01%
39,620
– –
ARWR icon
124
Arrowhead Research
ARWR
$12B
– –
-2,159,973
Closed -$15.9M
BMY icon
125
CALL
Bristol-Myers Squibb
BMY
$130B
– –
-100,000
Closed -$5.39M
2 3 4
5
6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q4 2016 Portfolio in Review

As of Q4 2016, OrbiMed held 151 positions worth $7.85B, down 11% from $8.78B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

OrbiMed withdrew a net $365M in Q4 2016, closing 20 positions and reducing 26 holdings. Its most notable exit was Wellcare Health Plans, Inc., an estimated $146M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Financials.

Against the trend, OrbiMed opened a new position in Elevance Health worth $147M.

  • OrbiMed's largest Q4 2016 buy was Elevance Health: 1,021,600 shares worth $147M.
  • OrbiMed added most to Alexion Pharmaceuticals in Q4 2016, an estimated $91.8M increase.
  • OrbiMed's biggest Q4 2016 reduction was Molina Healthcare, cutting an estimated $117M.
  • OrbiMed fully exited Wellcare Health Plans, Inc. in Q4 2016, selling an estimated $146M.
  • OrbiMed's ten largest holdings make up 37% of its $7.85B portfolio in Q4 2016.
  • OrbiMed opened 11 new positions and closed 20 in Q4 2016.
  • OrbiMed's portfolio value fell 11% quarter-over-quarter to $7.85B.

Based on OrbiMed's 13F filing for Q4 2016, filed 14 Feb 2017.